Heterozygous deletion of RB1 is also frequent in advanced prostate cancers, which is naturally associated with heterozygous loss of SUCLA2. Thymoquinone appeared to be effective to SUCLA2-heterozyous prostate cancers as well [100]. Here, SUCLA2 is linked to prostate carcinoma.